S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

$30.42
+0.28 (+0.93%)
(As of 03/28/2024 ET)
Today's Range
$29.61
$30.58
50-Day Range
$28.21
$37.78
52-Week Range
$27.92
$59.61
Volume
542,164 shs
Average Volume
653,468 shs
Market Capitalization
$1.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.57

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.7% Upside
$55.57 Price Target
Short Interest
Bearish
6.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of AtriCure in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$423,212 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

636th out of 938 stocks

Surgical & Medical Instruments Industry

64th out of 97 stocks

ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
ATRC May 2024 30.000 call
AtriCure (NASDAQ:ATRC) Downgraded by StockNews.com
AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $28.21
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
StockNews.com Upgrades AtriCure (NASDAQ:ATRC) to Hold
ATRC Apr 2024 22.500 put
AtriCure (ATRC) Fell on Competitor Action
AtriCure Full Year 2023 Earnings: EPS Beats Expectations
AtriCure price target raised by $1 at UBS, here's why
Cracking The Code: Understanding Analyst Reviews For AtriCure
Recap: AtriCure Q4 Earnings
AtriCure Q4 2023 Earnings Preview
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,200
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$55.57
High Stock Price Target
$68.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+84.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,440,000.00
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$399.24 million
Book Value
$9.84 per share

Miscellaneous

Free Float
46,924,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
1.39

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

5 analysts have issued 12 month price objectives for AtriCure's shares. Their ATRC share price targets range from $42.00 to $68.00. On average, they anticipate the company's share price to reach $55.57 in the next twelve months. This suggests a possible upside of 82.7% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the start of the year. Since then, ATRC shares have decreased by 14.8% and is now trading at $30.42.
View the best growth stocks for 2024 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,970,000 shares, an increase of 25.3% from the February 29th total of 2,370,000 shares. Based on an average daily volume of 618,100 shares, the days-to-cover ratio is presently 4.8 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Thursday, February, 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to analyst estimates of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 7.55%. The firm's revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.09) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of -0.820--0.740 for the period, compared to the consensus earnings per share estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.05%), Vanguard Group Inc. (10.01%), First Light Asset Management LLC (2.85%), Wellington Management Group LLP (2.79%), Nuveen Asset Management LLC (2.16%) and Dimensional Fund Advisors LP (2.11%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners